Article
Oncology
Uros Bumbasirevic, Marko Zivkovic, Milos Petrovic, Vesna Coric, Nikola Lisicic, Nebojsa Bojanic
Summary: In the treatment of seminoma, routine radiotherapy is no longer recommended for clinical stage I patients. Instead, a risk-adapted approach is preferred, with adjuvant carboplatin chemotherapy as the main treatment option. Active surveillance can prevent overtreatment but requires strict follow-up and increased radiation exposure.
Article
Oncology
Bela Mrinakova, Karol Kajo, Viera Lehotska, Martina Ondrusova, Sona Balogova, Zuzana Pinakova, Vera Novotna, Vanda Usakova, Lucia Fedorkova, Iveta Waczulikova, Juraj Kausitz, Dalibor Ondrus
Summary: This study compared the impact of active surveillance (S) and adjuvant chemotherapy (ACT) on the survival of patients with clinical stage I testicular seminoma. The results suggest that for high-risk patients, ACT may be a suitable treatment, while S is a viable option for low-risk patients.
Article
Oncology
J. Aparicio, X. Garcia del Muro, P. Maroto, J. Terrasa, D. Castellano, R. Bastus, J. Guma, N. Sagastibeltza, I Duran, S. Ochenduszko, J. A. Meana, J. Garcia-Sanchez, J. A. Arranz, R. Girones, J. R. Germa
Summary: In the context of risk-adapted treatment for stage I seminoma, administering two courses of AC to patients with tumor size > 4 cm and/or rete testis invasion is associated with a higher incidence of second recurrences but does not significantly modify the pattern of relapses or their outcome.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Goncagul Akdag, Ozkan Alan, Akif Dogan, Zeynep Yuksel, Sedat Yildirim, Oguzcan Kinikoglu, Emre Kudu, Heves Surmeli, Hatice Odabas, Mahmut Emre Yildirim, Nedim Turan
Summary: This study aimed to investigate the effects of treatment options on the prognosis of stage-I testicular seminoma patients. The results showed that adjuvant therapy did not significantly improve disease-free survival compared to active surveillance. Furthermore, lymphovascular invasion was identified as an important prognostic indicator for determining the treatment strategy and prognosis.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Mitchell M. Huang, Zhuo T. Su, Joseph G. Cheaib, Michael J. Biles, Mohamad E. Allaf, Hiten D. Patel, Phillip M. Pierorazio
Summary: The study shows that non-risk-adapted active surveillance (NRAS) is the most cost-effective management strategy for patients with clinical stage I (CSI) seminoma, offering the lowest per-patient healthcare cost and highest Quality-Adjusted Life Years (QALYs) gained over a 10-year period. NRAS also allows a high percentage of patients to avoid unnecessary treatment compared to current practice and risk-adapted active surveillance.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Urology & Nephrology
Muhannad Alsyouf, Siamak Daneshmand
Summary: The management of clinical stage II seminoma has shifted towards minimizing long-term morbidities while still achieving oncologic cure, with surgery emerging as an important treatment option for these patients. Studies such as SEMS and PRIMETEST have shown promising results for primary retroperitoneal lymph node dissection in clinical stage II seminoma.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Vasco Quaresma, Diogo Henriques, Lorenzo Marconi, Joao Lorigo, Ana-Marta Ferreira, Roberto Jarimba, Pedro Nunes, Arnaldo Figueiredo, Belmiro Parada
Summary: This study evaluated the clinical outcomes of 55 patients with stage I seminoma and analyzed the factors influencing treatment choice and oncological outcomes. The results showed that active surveillance is a safe modality, and adjuvant radiotherapy and adjuvant chemotherapy with carboplatin have similar results with fewer adverse effects in the chemotherapy group.
ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA
(2023)
Review
Medicine, General & Internal
Dong Hyuk Kang, Kang Su Cho, Jae Yong Jeong, Young Joon Moon, Doo Yong Chung, Hae Do Jung, Joo Yong Lee
Summary: This study suggests that there is no significant difference in overall survival between active surveillance (AS) and adjuvant treatment for patients of CSI seminoma within 5 years, but adjuvant treatment reduces the risk of recurrence within 5 years.
MEDICINA-LITHUANIA
(2022)
Article
Oncology
Isamu Tachibana, Andre Alabd, Yan Tong, Alex Piroozi, Mohammad Mahmoud, Sean Q. Kern, Timothy A. Masterson, Nabil Adra, Richard S. Foster, Nasser H. Hanna, Lawrence H. Einhorn, Clint Cary
Summary: This study confirmed the efficacy of surgery for CS II seminoma, avoiding the side effects of chemotherapy or radiotherapy. Patients with delayed development of CS II disease had the best surgical outcomes, and careful surveillance may prevent overtreatment in patients with borderline CS II disease.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Psychiatry
Gordon Y. Ye, Judy E. Davidson, Kristen Kim, Sidney Zisook
Summary: The study found no significant difference in suicide rates between physicians and non-physicians in the US, but the suicide rate among female physicians appeared slightly higher than among female non-physicians. Factors such as depressed mood, mental health problems, poor general health, and work-related stress were more commonly associated with physician suicides.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Article
Urology & Nephrology
Manar Mahmoud Sayed, Azza Mohamad Nasr, Ibtesam Mohamad Saad Eldin, Yasser Anwar Abdelazim
Summary: We retrospectively analyzed the impact of post-orchiectomy treatment modalities on the prognosis of clinical stage I seminoma patients who presented to our institute from 2005 to 2019. The results showed that regardless of the post-operative approach, the 5-year overall survival rate for all patients was 100%. The 5-year disease-free survival rate was 100% for patients who received adjuvant chemotherapy or radiotherapy, and 93% for patients who were kept under active surveillance.
ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA
(2023)
Article
Surgery
David T. Hughes, David Reyes-Gastelum, Kevin C. Ward, Ann S. Hamilton, Megan R. Haymart
Summary: Despite the belief among most physicians that active surveillance is an appropriate management option for thyroid cancer, only a minority of them actually use it in their practice. Barriers reported by physicians include patient resistance, concerns about loss to follow-up, patient anxiety, and worries about medical malpractice lawsuits. Addressing these barriers is crucial for improving the uptake of active surveillance.
Article
Gastroenterology & Hepatology
Nancy L. Schoenborn, Craig E. Pollack, Samir Gupta, Cynthia M. Boyd
Summary: This study examined physicians' decision-making on surveillance colonoscopies in older adults and found that recommendations varied depending on patient age, health status, and prior adenoma risk. Some physicians reported uncertainty regarding the balance of benefits and harms of surveillance in older adults and expressed the need for decision support tools. Further research is needed to evaluate the benefits and harms of surveillance colonoscopy in older adults and provide decision support tools to assist physicians and patients in making informed decisions.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Editorial Material
Hematology
Izidore S. Lossos
Summary: In a retrospective analysis by Bobillo et al, it was found that using R-CHOP or R-CHOP-like regimens to treat stage I DLBCL patients led to excellent overall outcomes. However, patients with extranodal presentation had worse prognosis compared to those with nodal disease. Consolidation with radiation therapy improved progression-free survival and overall survival in extranodal patients, particularly in PET-positive patients at the end of immunochemotherapy.
Article
Oncology
Sonja Levy, Stephanie A. Blankenstein, Dirk Jan Grunhagen, Mathilde Jalving, Olga Hamming-Vrieze, Lukas B. Been, Lisa Tans, Alexander C. J. van Akkooi, Margot E. T. Tesselaar
Summary: PORT is associated with reduced recurrence and overall mortality in stage I-III MCC patients in the Netherlands, but not with MCC-related mortality. Further refinement of PORT criteria is needed to address selection bias.
RADIOTHERAPY AND ONCOLOGY
(2022)